SCHEMBL1472570

SCHEMBL1472570

c1c[nH]c(-c2nnn[nH]2)n1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NISCH Q9Y2I1 2/20 0.42
MTOR P42345 1/20 0.42
ADK P55263 1/20 0.42
PDE4A P27815 1/20 0.39
PDE4B Q07343 1/20 0.39
PDE4C Q08493 1/20 0.39
PDE4D Q08499 1/20 0.39
ALDH1A1 P00352 4/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
KDM4E B2RXH2 2/20 0.35
PDE3B Q13370 1/20 0.35
PDE3A Q14432 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.34
SMPD3 Q9NY59 1/20 0.33
IDO1 P14902 1/20 0.33
ADRA2A P08913 2/20 0.33
CSNK1A1 P48729 1/20 0.33
TYRO3 Q06418 1/20 0.33
DYRK1B Q9Y463 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL81650 0.78 NISCH (0.59) NISCHMTORADKPDE4APDE4B
Hydrochloric Acid SCHEMBL1536214 0.75 NISCH (0.56) NISCHMTORADKPDE4APDE4B
SCHEMBL28425230 0.75 NISCH (0.56) NISCHMTORADKPDE4APDE4B
SCHEMBL101638 0.75
SCHEMBL22206279 0.72
Ammonia Solution, Strong SCHEMBL238233 0.72
SCHEMBL6649382 0.72
SCHEMBL216707 0.70
SCHEMBL13977589 0.69 NISCH (0.50) NISCHMTORADKPDE4APDE4B
SCHEMBL1554361 0.68 KDM4E (0.31) KDM4ESMN1; SMN2ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117613506-A Composite glass fiber diaphragm and preparation method thereof 陕西科技大学 2024-02-27 CN claimed
CN-110562976-A High-efficiency electrocatalytic material and preparation method thereof 深圳大学 2019-12-13 CN claimed
US-20170216248-A1 Enhanced Erythropoiesis and Iron Metabolism FIBROGEN, INC. 2017-08-03 US claimed
US-9217062-B2 C-substituted, 1H-azoles for amphoteric, solvent-less proton conductivity THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) 2015-12-22 US claimed
US-20140039132-A1 C-SUBSTITUTED, 1H-AZOLES FOR AMPHOTERIC, SOLVENT-LESS PROTON CONDUCTIVITY RICKS-LASKOSKI HOLLY L (US) 2014-02-06 US claimed
EP-2024385-A1 BETULIN DERIVED COMPOUNDS USEFUL AS ANTIBACTERIAL AGENTS Valtion Teknillinen Tutkimuskeskus (FI) 2009-02-18 EP claimed
WO-2007141389-A1 BETULIN DERIVED COMPOUNDS USEFUL AS ANTIBACTERIAL AGENTS VALTION TEKNILLINEN TUTKIMUSKESKUS (FI) 2007-12-13 WO claimed
EP-1140822-A1 STABLE ACTIVATED NOVEL CARBAMIC ACID DERIVATIVES, PREPARATION METHOD AND USE FOR PREPARING UREA Centre National de la Recherche Scientifique (FR) 2001-10-10 EP claimed
WO-2000042009-A1 STABLE ACTIVATED NOVEL CARBAMIC ACID DERIVATIVES, PREPARATION METHOD AND USE FOR PREPARING UREA CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2000-07-20 WO claimed
CN-117613506-A Composite glass fiber diaphragm and preparation method thereof 陕西科技大学 2024-02-27 CN disclosed
CN-110562976-A High-efficiency electrocatalytic material and preparation method thereof 深圳大学 2019-12-13 CN disclosed
CN-110562976-A High-efficiency electrocatalytic material and preparation method thereof 深圳大学 2019-12-13 CN disclosed
US-10428081-B2 EGFR inhibitor, preparation method and use thereof SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) 2019-10-01 US disclosed
US-20190100528-A1 EGFR INHIBITOR, PREPARATION METHOD AND USE THEREOF SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) 2019-04-04 US disclosed
WO-2004104005-A2 IMMUNOSUPPRESSIVE EFFECTS OF PTERIDINE DERIVATIVES 4 AZA BIOSCIENCE NV (BE) 2004-12-02 WO disclosed
US-5834176-A Silver halide photographic light-sensitive material KONICA CORPORATION (JP) 1998-11-10 US disclosed
EP-0752614-A2 Silver halide photographic light-sensitive material KONICA CORPORATION (JP) 1997-01-08 EP disclosed
EP-0188400-A2 Oligopeptides, intermediates and process for their preparation CIBA-GEIGY AG (CH) 1986-07-23 EP disclosed
US-4213986-A DERIVATIVES CONTAIN TETRAZOLE RING, TREATMENT OF PURINE METABOLIC DISORDER, ANTIURICOPATHIC HOECHST AKTIENGESELLSCHAFT (DE) 1980-07-22 US disclosed
US-4152440-A DIURETICS, ANALGESICS HOECHST AKTIENGESELLSCHAFT (DE) 1979-05-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170216248-A1 Enhanced Erythropoiesis and Iron Metabolism EPOR, TFRC, HAMP NISCH 3670/4885MTOR 1892/4885ADK 2503/4885
US-20190100528-A1 EGFR INHIBITOR, PREPARATION METHOD AND USE THEREOF EGFR, ERBB2, ERBB4 NISCH 3283/4885MTOR 865/4885ADK 255/4885
US-10428081-B2 EGFR inhibitor, preparation method and use thereof EGFR, ERBB2, ERBB4 NISCH 3283/4885MTOR 865/4885ADK 255/4885
US-20140039132-A1 C-SUBSTITUTED, 1H-AZOLES FOR AMPHOTERIC, SOLVENT-LESS PROTON CONDUCTIVITY H1-3, H1-4, HRH3 NISCH 483/4885MTOR 2629/4885ADK 3353/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.